Free Trial

Treace Medical Concepts (TMCI) Stock Price, News & Analysis

+0.22 (+3.76%)
(As of 06/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
840,581 shs
Average Volume
911,468 shs
Market Capitalization
$376.40 million
P/E Ratio
Dividend Yield
Price Target

Treace Medical Concepts MarketRank™ Stock Analysis

Analyst Rating
2.00 Rating Score
101.2% Upside
$12.21 Price Target
Short Interest
11.58% of Float Sold Short
Dividend Strength
News Sentiment
1.56mentions of Treace Medical Concepts in the last 14 days
Based on 6 Articles This Week
Insider Trading
Acquiring Shares
$2.93 M Bought Last Quarter
Proj. Earnings Growth
From ($0.89) to ($0.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.49 out of 5 stars

Medical Sector

275th out of 913 stocks

Surgical & Medical Instruments Industry

39th out of 100 stocks

TMCI stock logo

About Treace Medical Concepts Stock (NASDAQ:TMCI)

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

TMCI Stock Price History

TMCI Stock News Headlines

Unveiling 6 Analyst Insights On Treace Medical Concepts
See More Headlines
Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$187.12 million
Book Value
$2.24 per share


Free Float
Market Cap
$376.40 million
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. John T. TreaceMr. John T. Treace (Age 52)
    CEO, Founder & Director
    Comp: $1.09M
  • Mr. Mark L. Hair CPA (Age 54)
    Chief Financial Officer
    Comp: $599.7k
  • Mr. Aaron J. Berutti (Age 45)
    Senior Vice President of Sales
    Comp: $484.22k
  • Mr. Terry W. Lubben (Age 59)
    Senior Vice President of Operations
  • Mr. Taylor Erickson
    Chief Information & Security Officer
  • Ms. Julie D. Dewey (Age 63)
    Chief Communications & Investor Relations Officer
  • Mr. Scot M. Elder J.D. (Age 49)
    Chief Legal & Compliance Officer and Corporate Secretary
  • Mr. Nathan Minnich
    Senior Vice President of Marketing
  • Mr. Daniel E. Owens (Age 52)
    Chief Human Resources Officer
  • Dr. Sean F. Scanlan Ph.D. (Age 42)
    Chief Innovation Officer

TMCI Stock Analysis - Frequently Asked Questions

Should I buy or sell Treace Medical Concepts stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TMCI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TMCI, but not buy additional shares or sell existing shares.
View TMCI analyst ratings
or view top-rated stocks.

What is Treace Medical Concepts' stock price target for 2024?

7 equities research analysts have issued 1 year price objectives for Treace Medical Concepts' shares. Their TMCI share price targets range from $5.50 to $27.50. On average, they anticipate the company's stock price to reach $12.21 in the next twelve months. This suggests a possible upside of 101.2% from the stock's current price.
View analysts price targets for TMCI
or view top-rated stocks among Wall Street analysts.

How have TMCI shares performed in 2024?

Treace Medical Concepts' stock was trading at $12.75 on January 1st, 2024. Since then, TMCI shares have decreased by 52.4% and is now trading at $6.07.
View the best growth stocks for 2024 here

When is Treace Medical Concepts' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our TMCI earnings forecast

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) issued its earnings results on Tuesday, May, 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.30). The firm earned $51.11 million during the quarter, compared to analyst estimates of $49.07 million. Treace Medical Concepts had a negative trailing twelve-month return on equity of 39.66% and a negative net margin of 27.93%. The business's revenue was up 21.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.23) earnings per share.

What ETF holds Treace Medical Concepts' stock?

iShares U.S. Medical Devices ETF holds 284,937 shares of TMCI stock, representing 0.03% of its portfolio.

What guidance has Treace Medical Concepts issued on next quarter's earnings?

Treace Medical Concepts updated its FY 2024 earnings guidance on Wednesday, May, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $201.0 million-$211.0 million, compared to the consensus revenue estimate of $222.8 million.

When did Treace Medical Concepts IPO?

Treace Medical Concepts (TMCI) raised $150 million in an IPO on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Who are Treace Medical Concepts' major shareholders?

Treace Medical Concepts' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.97%), William Blair Investment Management LLC (3.77%), TimesSquare Capital Management LLC (2.24%), Wealth Enhancement Advisory Services LLC (0.39%), Oak Ridge Investments LLC (0.20%) and GSA Capital Partners LLP (0.11%). Insiders that own company stock include Aaron Berutti, Daniel E Owens, Deepti Jain, F Barry Bays, James T Treace, John R Treace, John T Treace, Mark Hair, Richard W Mott, Scot Michael Elder, Sean F Scanlan, Terry W Lubben and Thomas E Timbie.
View institutional ownership trends

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TMCI) was last updated on 6/13/2024 by Staff

From Our Partners